These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

900 related articles for article (PubMed ID: 27165836)

  • 21. Protective effect of rutin on lipids, lipoproteins, lipid metabolizing enzymes and glycoproteins in streptozotocin-induced diabetic rats.
    Stanely Mainzen Prince P; Kannan NK
    J Pharm Pharmacol; 2006 Oct; 58(10):1373-83. PubMed ID: 17034661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preferential uptake of intermediate-density lipoproteins from nephrotic patients by human mesangial and liver cells.
    Krämer-Guth A; Nauck M; Pavenstädt H; Königer M; Wieland H; Schollmeyer P; Wanner C
    J Am Soc Nephrol; 1994 Oct; 5(4):1081-90. PubMed ID: 7849247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid metabolism in nephrotic rats induced by daunomycin injection.
    Morisaki N; Matsuoka N; Saito Y; Kumagai A
    Metabolism; 1984 May; 33(5):405-10. PubMed ID: 6717274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels.
    Wang L; Shearer GC; Budamagunta MS; Voss JC; Molfino A; Kaysen GA
    Kidney Int; 2012 Nov; 82(9):990-9. PubMed ID: 22785171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects.
    Vuong TD; Stroes ES; Willekes-Koolschijn N; Rabelink TJ; Koomans HA; Joles JA
    Kidney Int; 1999 Mar; 55(3):1005-10. PubMed ID: 10027937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Physiology and pathophysiology of the metabolism of lipoproteins].
    Sandhofer F
    Wien Med Wochenschr; 1994; 144(12-13):286-90. PubMed ID: 8650930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Lipid metabolism abnormalities in Chronic Kidney Disease].
    Bianchi S; Baronti A; Cominotto R; Bigazzi R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression of renal failure: role of apolipoprotein B-containing lipoproteins.
    Attman PO; Samuelsson O; Alaupovic P
    Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-density lipoprotein metabolism in the nephrotic syndrome.
    Warwick GL; Caslake MJ; Boulton-Jones JM; Dagen M; Packard CJ; Shepherd J
    Metabolism; 1990 Feb; 39(2):187-92. PubMed ID: 2299990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria.
    Warwick GL; Packard CJ; Demant T; Bedford DK; Boulton-Jones JM; Shepherd J
    Kidney Int; 1991 Jul; 40(1):129-38. PubMed ID: 1921148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
    Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High density lipoproteinuria in nephrotic syndrome.
    de Mendoza SG; Kashyap ML; Chen CY; Lutmer RF
    Metabolism; 1976 Oct; 25(10):1143-9. PubMed ID: 184367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine.
    Shafrir E
    Isr J Med Sci; 1996 Jun; 32(6):390-7. PubMed ID: 8682644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein profiles in a heterogeneous group of patients with nephrotic syndrome.
    Michaeli J; Bar-On H; Shafrir E
    Isr J Med Sci; 1981 Nov; 17(11):1001-8. PubMed ID: 7319786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome.
    Warwick GL; Packard CJ; Murray L; Grierson D; Stewart JP; Shepherd J; Boulton-Jones JM
    Clin Sci (Lond); 1992 Jun; 82(6):701-8. PubMed ID: 1320552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome.
    Vaziri ND; Kim CH; Phan D; Kim S; Liang K
    Kidney Int; 2004 Jul; 66(1):262-7. PubMed ID: 15200432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome.
    Shearer GC; Stevenson FT; Atkinson DN; Jones H; Staprans I; Kaysen GA
    Kidney Int; 2001 Jan; 59(1):179-89. PubMed ID: 11135070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats.
    Moritomo Y; Hirano T; Ebara T; Kurokawa M; Naito H; Furukawa S; Nagano S
    Nephron; 1994; 67(2):218-25. PubMed ID: 8072613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
    Vega GL; Grundy SM
    Kidney Int; 1988 Jun; 33(6):1160-8. PubMed ID: 3165483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.